

PRESS CLIPPING SHEET

PUBLICATION:	Business Today
DATE:	June-2017
COUNTRY:	Egypt
CIRCULATION:	9,500
TITLE :	Sandoz Egypt launches its first recombinant human growth hormone deficiency patients
PAGE:	62
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Staff Report
AVE:	3,050

Sandoz Egypt launches its first recombinant human growth hormone to treat growth hormone deficiency patients

Sandoz, a Novartis Division, announced today a breakthrough for Growth Hormone Deficiency (GHD) patients in Egypt via launching the first follow-on version of a biopharmaceutical medicine approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Sandoz, the global leader in biosimilars, has seven decades of experience in biotechnologies using state-of-the-art technologies and facilities," said Thodoris Dimopoulos, Sandoz Country Head, Egypt and Libya. "The launch of our first Sandoz biologic medicine in Egypt, is not only a milestone for the company, but more importantly it paves the way for redefining patients' access to treatment by offering a high-quality, more affordable version of this important medicine."

"Sandoz maintains its commitment to bringing high-quality biologic medicines to patients and healthcare professionals around the world. Sandoz' purpose is to discover new ways to improve people's lives, by pioneering novel approaches to help people around the world access high-quality medicine and contributing to improving society's ability to support growing healthcare needs," said Dimopoulos.

"A growth hormone deficiency (GHD) occurs when the pituitary gland doesn't produce enough growth hormone. It more commonly affects children than adults, occurring in roughly 1 in 7,000 births," said Dr. Mona Salem, Professor of Pediatric Endocrinology and Diabetes at Ain Shams University and Vice President of the Egyptian Pediatric Endocrinology and Diabetes Society. "Growth hormone deficiency is treatable. Children who are diagnosed early often recover very well. Children with congenital GHD are often treated with growth hormone until they reach puberty. However, some remain in treatment for their entire lives."